These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36915460)

  • 1. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
    Wan Y; Luo D
    J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
    He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
    J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study.
    Tao J; Zhang Y; Wang Y; Huang S; Gao W; Dai L; Feng Z; Jiao C; Zhang Y
    J Gastrointest Oncol; 2024 Apr; 15(2):630-640. PubMed ID: 38756629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
    Li L; Wang T; Wu Z; Li Y; Ma H; Wang L; Lei S; Chen W
    Transl Cancer Res; 2023 Nov; 12(11):3034-3044. PubMed ID: 38130300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
    Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
    J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report.
    Wang Y; Li J; Xu Q; Li K; Zhang C; Chen P
    J Gastrointest Oncol; 2022 Oct; 13(5):2667-2671. PubMed ID: 36388671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
    Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
    Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
    Chen Y; Zhou YW; Cheng K; Li ZP; Luo DY; Qiu M; Li Q; Wang X; Shen YL; Cao D; Yang Y; Bi F; Liu JY; Gou HF
    Oncologist; 2021 Aug; 26(8):e1320-e1326. PubMed ID: 33830591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
    Zhang Y; Zou JY; Wang Z; Wang Y
    Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
    Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
    J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.
    Xu X; Yu Y; Liu M; Liang L; Liu T
    Transl Cancer Res; 2022 Jan; 11(1):276-287. PubMed ID: 35261903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review.
    Li Y; Chen X; Li W; Ye Y; Du X; Sun S; Liu L; Zhang H
    Front Oncol; 2021; 11():684309. PubMed ID: 34109130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
    Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
    Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
    Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
    Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
    Front Oncol; 2020; 10():587692. PubMed ID: 33282739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
    Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
    Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of raltitrexed plus S-1
    Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
    Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.